SYGNIS, a stock-listed company based in Heidelberg, Germany, merged with X-Pol Biotech (now renamed: SYGNIS Biotech) in December 2012 and thus realigned its business.
The Company was founded in 1997 under the name LION Bioscience AG and went public in 2000. In 2006, the Company realigned in the field of drug development and was renamed as SYGNIS Pharma AG. At the end of 2012, we stopped the drug development activities and the merger with X-Pol Biotech transformed the Company to a developer of molecular biology products for genomic and proteomic applications. Since 2013 the Company’s name is SYGNIS AG.
X-Pol Biotech was established in May 2008 in Madrid, Spain, and focuses its research and development (R&D) on biotechnological applications of polymerases. The company was founded by Professor Luis Blanco, and Professor Margarita Salas joined later as a shareholder and scientific advisor (see Advisors).